MARKET

BLPH

BLPH

Bellerophon Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8910
+0.0432
+5.09%
Closed 16:00 05/16 EDT
OPEN
0.8600
PREV CLOSE
0.8478
HIGH
0.9328
LOW
0.8600
VOLUME
15.12K
TURNOVER
8.35K
52 WEEK HIGH
5.95
52 WEEK LOW
0.6700
MARKET CAP
8.50M
P/E (TTM)
-0.4768
1D
5D
1M
3M
1Y
5Y
Avantor Names Jonathan Peacock Chairman
MT Newswires · 3d ago
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster ...
GlobeNewswire · 4d ago
Recap: Bellerophon Therapeutics Q1 Earnings
Bellerophon Therapeutics (NASDAQ:BLPH) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 4d ago
90 Biggest Movers From Yesterday
  Losers
Benzinga · 6d ago
Bellerophon Therapeutics GAAP EPS of -$1.87
Bellerophon Therapeutics press release (NASDAQ:BLPH): FY GAAP EPS of -$1.87. As of December 31, 2021, the company had cash and cash equivalents of $24.7 million, compared to cash and cash
Seekingalpha · 03/31 20:45
We Think Bellerophon Therapeutics (NASDAQ:BLPH) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 03/02 09:32
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Nas...
GlobeNewswire · 01/10 12:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) shares increased by 8.19% to $6.6 during Thursday's after-market session. The company's market cap stands at $45.6 million.
Benzinga · 12/23/2021 21:40
More
No Data
Learn about the latest financial forecast of BLPH. Analyze the recent business situations of Bellerophon Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BLPH stock price target is 24.50 with a high estimate of 30.00 and a low estimate of 19.00.
High30.00
Average24.50
Low19.00
Current 0.8910
EPS
Actual
Estimate
-0.53-0.40-0.26-0.13
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 5.39M
% Owned: 56.48%
Shares Outstanding: 9.55M
TypeInstitutionsShares
Increased
7
54.41K
New
5
110.22K
Decreased
4
73.08K
Sold Out
5
43.12K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
Naseem Amin
Chief Executive Officer
Peter Fernandes
Chief Financial Officer/Chief Accounting Officer/Secretary
Nicholas Laccona
Vice President - Operations
Parag Shah
Vice President
Martin Dekker
Independent Director
Scott Bruder
Independent Director
Mary Cloyd
Independent Director
Crispin Teufel
Independent Director
Theodore Wang
No Data
No Data
About BLPH
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing the products that addresses unmet medical needs in the treatment of cardiopulmonary diseases. It is engaged in the development of nitric oxide therapy for patients with or at risk of pulmonary hypertension, or PH, using pulsatile nitric oxide delivery platform, INOpulse. INOpulse is a technology used in hospitals to deliver continuous flow of inhaled nitric oxide. Nitric oxide is naturally produced and released by the lining of the blood vessels and results in vascular smooth muscle relaxation, an important factor in regulating blood pressure. The Company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis as well as other pulmonary fibrosing diseases. The Company completed Phase II clinical trial.

Webull offers kinds of Bellerophon Therapeutics Inc stock information, including NASDAQ:BLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLPH stock methods without spending real money on the virtual paper trading platform.